Medicine company Eli Lilly and Company (NYSE: LLY) and biopharmaceutical company Morphic Holding Inc (NASDAQ: MORF) on Monday announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical firm developing oral integrin therapies for serious chronic diseases.
Morphic's lead program, MORF-057, a selective oral small molecule inhibitor of α4β7 integrin, targets inflammatory bowel disease (IBD) and is undergoing Phase 2 studies in ulcerative colitis and Crohn's disease. Morphic also has a preclinical pipeline for autoimmune diseases, pulmonary hypertensive diseases, fibrotic diseases and cancer.
Lilly will launch a tender offer to purchase all Morphic shares at USD57 per share in cash, totaling approximately USD3.2bn. This represents a 79.0% premium to the closing stock price on 5 July 2024. The transaction, approved by both companies' boards, is expected to close in Q3 2024, subject to customary conditions.
Lilly's financial results will reflect the acquisition as a business combination or asset acquisition per GAAP. Citi and Kirkland & Ellis LLP are advising Lilly, while Centerview Partners LLC, Evercore Group L.L.C. and Fenwick & West LLP are advising Morphic.
With nearly 150-year history of pioneering life-changing medicines, Lilly aims to improve patient outcomes and expand treatment options for IBD with this acquisition.
Dragonfly Therapeutics names new chief financial officer
Sun Pharma's LEQSELVI 8mg tablets receive US FDA approval
FDA feedback boosts Diamyd Medical's pathway to accelerated approval for Type 1 Diabetes Therapy
Atara Biotherapeutics gains FDA Priority Review for tabelecleucel
Kyverna's KYV-101 granted FDA Regenerative Medicine Advanced Therapy designation
Lilly to acquire Morphic to enhance inflammatory bowel disease treatments
BioSenic expands US patent portfolio for ATO use in sepsis treatment
BenevolentAI and AstraZeneca collaboration leads to novel target for lupus
UCB announces results from three studies supporting the value of CIMZIA(R) (certolizumab pegol)
Henlius and Organon report success of HLX14 Phase 3 study
Nobelpharma's inhaled use of Leukine receives Japanese regulatory approval to treat aPAP